Japan Generics Market Analysis

RNCOS
February 1, 2012
55 Pages - SKU: CICQ6800354
Countries covered: Japan

Japan is the world’s second largest pharmaceutical markets in the world, but due to public perception, the share of generic drugs has remained low in it. However, worried over rising healthcare expenses and high mortality rates, the government has now been playing a vital role in promoting generics. The patent expiry of branded drugs and active ingredients will also act as a strong growth driver for the market in future. According to the findings of our latest report, the generics market in Japan stood at around US$ 9 Billion in 2010. It estimates that the growth in generic drugs will outshine the expansion in overall pharmaceutical market.

According to “Japan Generics Market Analysis”, Japan is expected to be the next generic hub, and cancer related generics exhibit vast potential. The report finds out how vital is the role of National Health Insurance (NHI) pharmacies and Diagnosis Procedure Combination (DPC) hospitals in the industry development. It was observed that the DPC hospitals, in particular, have been growing at a robust rate, promoting generics penetration. We also found that ethical generics hold the majority share in the generic drugs market.

A detailed demographic analysis was carried out in the research that revealed that the population aged 65 years and above accounts for maximum healthcare-related expenditures in Japan, and hence becomes the target population for generics promotion. Further, a meticulous disease and age-wise segmentation has provided the holistic understanding of the healthcare-related demand parameters prevailing in the country.

The government in Japan has taken several initiatives to ensure growth and promotion of generics industry in the country. Recently, special premium-based incentives have been given to pharmacists on generic promotion. In near future, the government plans to bring in more reforms in medical care system. Our research talks about such revisions and reforms briefly to present a balanced outlook of the industry to clients. Analysis of current trends, profiles of key players in the Japanese generic market, and recent developments in the industry have also been included in the comprehensive study.



More Manufacturing, Packaging & Detailing reports by RNCOS

Global - API Market Outlook 2018 by RNCOS
Global API Market Outlook 2018 The recent spurt in emerging markets has directly impacted the pharmaceutical industry. Rising affordability, enhanced life expectancy and improved standard ...
Global - Cancer Generics Market Outlook 2018 by RNCOS
Global Cancer Generics Market Outlook 2018 With the advent of novel and innovative technologies, industries like healthcare and pharmaceutical are scaling newer heights. One such ...
Russian Pharmaceutical Market Outlook to 2017 by RNCOS
Russian Pharmaceutical Market Outlook to 2017 The pharmaceutical industry in Russia finally seems ready for a change. With the government adopting ‘Strategy 2020’ to improve ...
Cancer Generics Market Outlook 2017 by RNCOS
The National Cancer Institute has stated that almost half of the population born today will be diagnosed with cancer at some point during their lifetime. ...
See all reports like this >>

More Japan Manufacturing, Packaging & Detailing reports

Pharmaceuticals and Healthcare Report - Japan Q4 2014 by Business Monitor International
Pharmaceuticals and Healthcare Report - Japan Q4 2014BMI View: The weak Japanese yen, coupled with biennial medicine price cuts, will negatively impactmultinational pharmaceutical firms operating ...
Japan Pharmaceuticals and Healthcare Report Q3 2014 by Business Monitor International
Japan Pharmaceuticals and Healthcare Report Q3 2014BMI View: The Japanese government's push to increase generic drug use will benefit generic drugmanufacturers, particularly local firms. However, ...
Pharmaceuticals in Japan: ISIC 2423 by Euromonitor International
Pharmaceuticals in Japan: ISIC 2423Euromonitor International's Industrial reports provide a 360 degree view of an industry. The Industrial market report offers a comprehensive guide to ...
PharmaPoint: Type 2 Diabetes - Japan Drug Forecast and Market Analysis to 2022 by GlobalData
PharmaPoint: Type 2 Diabetes - Japan Drug Forecast and Market Analysis to 2022SummaryGlobalData has released its new Country report, “PharmaPoint: Type 2 Diabetes - Japan ...
See all reports like this >>

More Japan reports

D&B Country Report: Japan by Dun & Bradstreet Inc.
D&B Country Report. Comprehensive information for evaluating risks and opportunities when trading or investing in this country. Providing critical information and analysis on ...
See all reports like this >>

 

SELECT A LICENSE

    Online Download  USD 1,000  
    Hard Copy Mail Delivery  USD 1,100  
    CD-ROM Mail Delivery  USD 1,100  
    Global Site License  USD 1,500  
 
US: 800.298.5699
Int'l: +1.240.747.3093
 

Share this report


    Other tasks

     
     
    Join Alert Me now!
    Receive bi-weekly email alerts on new market research

    Sign up today!